Establishing Dosing Recommendations for Efavirenz in HIV/TB-Coinfected Children Younger Than 3 Years.

BACKGROUND CYP2B6 516 genotype-directed dosing improves efavirenz (EFV) exposures in HIV-infected children younger than 36 months, but such data are lacking in those with tuberculosis (TB) coinfection. METHODS Phase I, 24-week safety and pharmacokinetic (PK) study of EFV in HIV-infected children aged 3 to <36 months, with or without TB. CYP2B6 516 genotype classified children into extensive metabolizers (516 TT/GT) and poor metabolizers [(PMs), 516 TT]. EFV doses were 25%-33% higher in children with HIV/TB coinfection targeting EFV area under the curve (AUC) 35-180 μg × h/mL, with individual dose adjustment as necessary. Safety and virologic evaluations were performed every 4-8 weeks. RESULTS Fourteen children from 2 African countries and India with HIV/TB enrolled, with 11 aged 3 to <24 months and 3 aged 24-36 months, 12 extensive metabolizers and 2 PMs. Median (Q1, Q3) EFV AUC was 92.87 (40.95, 160.81) μg × h/mL in 8/9 evaluable children aged 3 to <24 months and 319.05 (172.56, 360.48) μg × h/mL in children aged 24-36 months. AUC targets were met in 6/8 and 2/5 of the younger and older age groups, respectively. EFV clearance was reduced in PM's and older children. Pharmacokinetic modeling predicted adequate EFV concentrations if children younger than 24 months received TB-uninfected dosing. All 9 completing 24 weeks achieved viral suppression. Five/14 discontinued treatment early: 1 neutropenia, 3 nonadherence, and 1 with excessive EFV AUC. CONCLUSIONS Genotype-directed dosing safely achieved therapeutic EFV concentrations and virologic suppression in HIV/TB-coinfected children younger than 24 months, but further study is needed to confirm appropriate dosing in those aged 24-36 months. This approach is most important for young children and currently a critical unmet need in TB-endemic countries.

[1]  A. Schellekens,et al.  Neuropsychiatric symptoms in Tanzanian HIV-infected children receiving long-term efavirenz treatment: a multicentre, cross-sectional, observational study. , 2019, The lancet. HIV.

[2]  D. Greenblatt,et al.  Effect of Rifampin-Isoniazid-Containing Antituberculosis Therapy on Efavirenz Pharmacokinetics in HIV-Infected Children 3 to 14 Years Old , 2018, Antimicrobial Agents and Chemotherapy.

[3]  A. Odone,et al.  Antiretroviral Therapy in HIV-Infected Children With Tuberculosis: A Systematic Review , 2017, The Pediatric infectious disease journal.

[4]  W. Borkowsky,et al.  CYP2B6 genotype-directed dosing is required for optimal efavirenz exposure in children 3–36 months with HIV infection , 2017, AIDS.

[5]  N. Bouazza,et al.  Pharmacokinetics of Efavirenz at a High Dose of 25 Milligrams per Kilogram per Day in Children 2 to 3 Years Old , 2017, Antimicrobial Agents and Chemotherapy.

[6]  B. Kampmann,et al.  The impact of HIV and antiretroviral therapy on TB risk in children: a systematic review and meta-analysis , 2017, Thorax.

[7]  P. Denti,et al.  The impact of genetic polymorphisms on the pharmacokinetics of efavirenz in African children , 2016, British journal of clinical pharmacology.

[8]  Lang Li,et al.  Rifampin enhances cytochrome P450 (CYP) 2B6-mediated efavirenz 8-hydroxylation in healthy volunteers. , 2016, Drug metabolism and pharmacokinetics.

[9]  L. Bertilsson,et al.  Is there a need to increase the dose of efavirenz during concomitant rifampicin-based antituberculosis therapy in sub-Saharan Africa? The HIV-TB pharmagene study. , 2015, Pharmacogenomics.

[10]  A. Walker,et al.  Routine versus clinically driven laboratory monitoring and first-line antiretroviral therapy strategies in African children with HIV (ARROW): a 5-year open-label randomised factorial trial , 2013, The Lancet.

[11]  Arrow trial team.  Routine versus clinically driven laboratory monitoring and first-line antiretroviral therapy strategies in African children with HIV (ARROW): a 5-year open-label randomised factorial trial , 2013 .

[12]  W. Moss,et al.  Effectiveness of Efavirenz-Based Regimens in Young HIV-Infected Children Treated for Tuberculosis: A Treatment Option for Resource-Limited Settings , 2013, PloS one.

[13]  G. Maartens,et al.  The Safety, Effectiveness and Concentrations of Adjusted Lopinavir/Ritonavir in HIV-Infected Adults on Rifampicin-Based Antitubercular Therapy , 2012, PloS one.

[14]  G. Maartens,et al.  Lopinavir Exposure is Insufficient in Children Given Double Doses of Lopinavir/Ritonavir during Rifampicin-Based Treatment for Tuberculosis , 2011, Antiviral therapy.

[15]  L. Kuhn,et al.  Antiretroviral Therapy Outcomes in HIV-Infected Children after Adjusting Protease Inhibitor Dosing during Tuberculosis Treatment , 2011, PloS one.

[16]  G. Maartens,et al.  Population pharmacokinetics of lopinavir and ritonavir in combination with rifampicin-based antitubercular treatment in HIV-infected children , 2010, Antiviral therapy.

[17]  T. Snyman,et al.  Presence of the CYP2B6 516G> T polymorphism, increased plasma Efavirenz concentrations and early neuropsychiatric side effects in South African HIV-infected patients , 2010, AIDS research and therapy.

[18]  T. Shangguan,et al.  Bioavailability in healthy adults of efavirenz capsule contents mixed with a small amount of food. , 2010, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.

[19]  S. Swaminathan,et al.  Dose adjustment of the non-nucleoside reverse transcriptase inhibitors during concurrent rifampicin-containing tuberculosis therapy: one size does not fit all , 2010, Expert opinion on drug metabolism & toxicology.

[20]  S. Spector,et al.  CYP2B6 genetic variants are associated with nevirapine pharmacokinetics and clinical response in HIV-1-infected children , 2007, AIDS.

[21]  M. Hughes,et al.  Long-term Safety and Efficacy of a Once-Daily Regimen of Emtricitabine, Didanosine, and Efavirenz in HIV-Infected, Therapy-Naive Children and Adolescents: Pediatric AIDS Clinical Trials Group Protocol P1021 , 2007, Pediatrics.

[22]  S. Spector,et al.  Efavirenz Pharmacokinetics in HIV-1-Infected Children Are Associated With CYP2B6-G516T Polymorphism , 2007, Journal of acquired immune deficiency syndromes.

[23]  A. Vibhagool,et al.  Efavirenz 600 mg/day versus efavirenz 800 mg/day in HIV-infected patients with tuberculosis receiving rifampicin: 48 weeks results , 2006, AIDS.

[24]  David A. Flockhart,et al.  The Cytochrome P450 2B6 (CYP2B6) Is the Main Catalyst of Efavirenz Primary and Secondary Metabolism: Implication for HIV/AIDS Therapy and Utility of Efavirenz as a Substrate Marker of CYP2B6 Catalytic Activity , 2003, Journal of Pharmacology and Experimental Therapeutics.

[25]  J. Pachón,et al.  Pharmacokinetic Interactions Between Efavirenz and Rifampicin in HIV-Infected Patients with Tuberculosis , 2002, Clinical pharmacokinetics.

[26]  S. P. Akpabio.  World Health Organisation , 1983, British Dental Journal.